Related Experiment Video
Updated: Aug 9, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
Update on endothelins - biology and clinical implications
1Division of Pediatric Nephrology, Vanderbilt University Medical Center, 1161 21st Avenue South, C-4204 MCN, Nashville, TN 37232-2584, USA.
Pediatric Nephrology (Berlin, Germany)
|August 21, 2001
Summary
Endothelin, a potent vasoconstrictor, is crucial for fetal development and a target for treating heart failure and hypertension. Research is advancing endothelin antagonism for clinical applications.
Area of Science:
- Cardiovascular Biology
- Developmental Biology
- Pharmacology
Background:
- Endothelin (ET) discovered a decade ago is a potent vasoconstrictor.
- ET biology, including isoforms, biosynthesis, receptors, and roles in disease, is increasingly understood.
- ET plays a significant role in various pathological conditions.
Purpose of the Study:
- To review the advancements in endothelin research over the past decade.
- To highlight the therapeutic potential of endothelin antagonism.
- To discuss the novel findings on endothelin's role in fetal development.
Main Methods:
- Literature review and synthesis of recent research findings.
- Analysis of studies on endothelin isoforms and receptor interactions.
- Examination of clinical data and preclinical studies on endothelin antagonism.
Main Results:
- Endothelin's potent vasoconstrictive properties are well-established.
- Endothelin antagonism shows promise for treating congestive heart failure and hypertension.
- Endothelin is vital for normal fetal maturation, particularly cardiac and enteric development.
Conclusions:
- Endothelin research has significantly advanced, revealing its complex roles.
- Endothelin antagonism is nearing clinical application for cardiovascular diseases.
- Endothelin's critical role in fetal development opens new avenues for research.
More Related Videos
Related Concept Videos
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:25Acute Inflammation III: Local and Systemic Effects
Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...